Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR) is a Healthcare stock tracked by StreetAlpha. It last closed at $46.99 on Oct 1. NKTR reports earnings on Thu, Nov 5, 2026. The average 12-month price target from 4 analysts is $111.50 (+137.3% from the last close), with a high of $178.00 and a low of $50.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in NKTR, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on NKTR in the past 90 days. The average target is $111.50, with a high of $178.00 and a low of $50.00, compared with the last close of $46.99.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | BTIG | Reiterated | Buy | $178 |
| Sep 23 | Wedbush | Maintained | Hold | $50 |
| Aug 21 | JP Morgan | Reinstated | Hold | $65 |
| Jul 22 | Canaccord Genuity | Initiated | Buy | $153 |
Whale Options Flow
90DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTR is in one of them and how their past NKTR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NKTR in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.